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Abstract
Background: Gene expression is widely used for the characterisation of breast cancers. Variability due to
tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect
measurements but is poorly documented. We studied the variability of global gene expression between core-
cuts of primary ER+ breast cancers and the impact of delays to tissue stabilisation due to sample X-ray and
of diagnostic core cutting.
Methods: Twenty-six paired core-cuts were taken immediately after tumour excision and up to 90 minutes
delay due to sample X-ray; 57 paired core-cuts were taken at diagnosis and 2 weeks later at surgical excision.
Whole genome expression analysis was conducted on extracted RNA. Correlations and differences were
assessed between the expression of individual genes, gene sets/signatures and intrinsic subtypes.
Results: Twenty-three and 56 sample pairs, respectively, were suitable for analysis. The range of correlations
for both sample sets were similar with the majority being >0.97 in both. Correlations between pairs for 18
commonly studied genes were also similar between the studies and mainly with Pearson correlation coefficients >0.6
except for a small number of genes, which had a narrow-dynamic range (e.g. MKI67, SNAI2). There was no systematic
difference in intrinsic subtyping between the first and second sample of either set but there was c.15 % discordance
between the subtype assignments between the pairs, mainly where the subtyping of individual samples was less
certain. Increases in the expression of several stress/early-response genes (e.g. FOS, FOSB, JUN) were found in both
studies and confirmed findings in earlier smaller studies. Increased expression of IL6, IGFBP2 and MYC (by 17 %, 14 %
and 44 %, respectively) occurred between the samples taken 2 weeks apart and again confirmed findings from an
earlier study.
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Conclusions: There is generally good correlation in gene expression between pairs of core-cuts except where genes
have a narrow dynamic range. Similar correlation coefficients to the average gene expression profiles of intrinsic
subtype, particularly LumA and LumB, can lead to discordances between assigned subtypes. Substantial changes in
expression of early-response genes occur within an hour after surgery and in IL6, IGFB2 and MYC as a result of
diagnostic core-cut biopsy.
Trial registration: Trial number CRUK/07/015. Study start date September 2008.
Keywords: Breast cancer, Gene expression, Heterogeneity
Background
Molecular analyses of primary breast cancer for both re-
search and patient management are now commonplace.
Measurements may be made on diagnostic core-cut bi-
opsies or surgical excisions that frequently comprise a
very small fraction of the tumour. In so-called window-
of-opportunity studies patients are exposed to medical
therapy between diagnosis and surgery [1] and compari-
sons are made between samples taken at both time
points. Valid interpretation of these studies depends on
knowledge of any variability or systematic changes in the
respective biomarkers that occur in the absence of treat-
ment. Variability/heterogeneity may lead to false rejec-
tion of a true effect while systematic differences between
diagnostic and surgical specimens may lead to artifactual
changes being falsely ascribed to an intervention. For ex-
ample, we have previously described the highly signifi-
cant impact of specimen type (core-cut vs excision) on
pAKT and pERK1/2 staining [2]. Pre-treatment/post-
treatment comparison of biomarkers might also be af-
fected by the taking of the diagnostic biopsy and changes
due to cold ischaemia between resection and tissue
stabilisation/fixation.
The effect of cold ischaemia time has been studied in
small cohorts of breast cancer with up to 24 hours
elapsed time before fixation, snap freezing or placement in
RNA later [3–5]. No studies have directly examined the
impact of the short time delay (20–60 minutes) resulting
from sending specimens for X-ray, a frequent practice
during breast cancer surgery to ensure the removal of the
lesion (e.g. non-palpable mass, calcifications) and/or to
check for adequate surgical margins, even in clinically
palpable tumours. A small number of studies have evalu-
ated gene expression changes over a longer period of time
between biopsies [6–8]. For example, Jeselsohn identified
14 genes, including nine immune-related that differed
between core-cuts and excision taken from 21 patients 6–
65 days apart (mean 30 days).
Our primary objectives were to use genome-wide ex-
pression profiling to determine more comprehensively
the variability and systematic changes in the expression
of genes or pre-specified gene sets or subtype classifica-
tions (i) between two core biopsies taken (A) immediately
after excision and (B) after sample X-ray and (ii) between
diagnostic core biopsies (D) and surgical core biopsies (S)
two weeks later in the absence of any intervention.
Methods
Patients and tissues
Study I. To answer the first objective we accessed tissues
collated from a previously published study [2]. Core-cut
biopsies (14-gauge needle) were taken from 26 surgical
specimens and placed in RNAlater immediately after re-
section (sample A) and again after X-ray of the excised
tumour (sample B). The time elapsed between samples
A and B was recorded in the surgical report form.
Study II. To answer the second objective we accessed
tissues from the no-treatment arm of The PeriOperative
Endocrine Therapy - Individualising Care (POETIC) trial
that randomized post-menopausal patients with primary
ER+ breast cancer from 120 UK centres (2:1) to receive
2 weeks’ non-steroidal aromatase inhibitor (AI) or no-
treatment for 2 weeks prior to surgery [1, 9].
At least one RNAlater-stored sample was available
from 33.5 % (1493/4456) of patients or paired from
13.2 % (589/4456) of patients of the POETIC trial. A
total of 227 control samples were subjected to RNA ex-
traction. Expression analyses were conducted when a
pair of RNA extracts was available with RIN >4. This
amounted to 57 pairs of samples from control patients
taken at diagnosis (D) and surgery (S).
Ethics statement
Patient consent and ethics approval for the collection
and analysis of breast cancer tissue samples was pro-
vided by the Royal Marsden Hospital for study I. Ethical
approval for POETIC (Trial number CRUK/07/015) was
provided by the National Research Ethics Service (NRES)
Committee London – South East.
Gene expression analysis, data pre-processing, data
analyses and statistical methods
The detailed methodology is described in the Additional
file 1.
In brief, extracted RNA was amplified, labeled and hy-
bridized on Illumina global gene expression BeadChips
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(Illumina San Diego, CA, USA). Illumina raw data was
extracted using GenomeStudio software and trans-
formed, normalized and batch-corrected. Paired samples
were excluded from further analysis if their fraction of
detected genes was <30 % and probes were filtered out if
they were not detected in any sample. Gene expression
data from this study is deposited at GEO (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73237)
with accession number GSE73237.
Entrez Gene ID was used as gene identifier in gene
signatures. The HumanHT-12_V4_0_R2_15002873_B
annotation file was used to map the Entrez Gene IDs to
the corresponding Illumina probe IDs. Gene signature
scores were weighted averages.
We evaluated three candidate gene sets: (i) metagene
wound healing signature [10]; (ii) immune-response
metagene [9]; and (iii) 13 of the 14 genes identified as
changing in the Jeselsohn study [6] (SNAI1 was not
detected on the Illumina platform). We also studied the
effects on 18 pre-specified genes that we selected as
being particularly relevant to breast cancer from prior
studies.
Each tumour sample was classified into one of the five
intrinsic subtypes based on the PAM50 classifier as
described in the Additional file 1.
Pearson and Spearman correlations were used to as-
sess the associations. Univariate paired or unpaired t
tests together with multivariate permutation tests were
used to identify differentially expressed genes between
the paired samples. The significantly differentially ex-
pressed genes were subjected to Ingenuity Pathway
Analysis (IPA). The significance of the difference be-
tween two correlation coefficients obtained in study I
and study II respectively was calculated using the Fisher
r-to-z transformation [11]. GraphPad Prism 6 (Graphpad
Software Inc., La Jolla, CA, USA) was used for some of
the statistical analyses in this study.
Results
Study I
Sufficient RNA was available from 26 sample pairs with
up to 90 minutes between samples A and B. Three pairs
were excluded due to low fraction of detected genes,
leaving 23 pairs with a time interval of 20–60 minutes
(median 30) for downstream data analysis. Patient demo-
graphics are described in Additional file 2: Table S1.
Variability in gene expression between samples
On hierarchical clustering 16 (70 %) of the pairs clus-
tered together (Fig. 1a). The correlation of the gene
expression for the 24,395 probes between samples A
and B provides an overall assessment of the similarity
of transcriptional profiles between the samples. The
Pearson correlation coefficient r values ranged from
0.91 to >0.99 (Additional file 3: Figure S1). Nine se-
lected pairs in Additional file 3: Figure S2 represent
the range of variability: three sets of three pairs with
a coefficient >0.99, 0.98 or 0.91–0.94. Correlation was
also determined between paired expression levels of
18 pre-selected genes frequently reported in breast
cancer (Additional file 2: Table S2, Additional file 3:
Figure S3). The correlation was above >0.6 and highly
statistically significant for all genes, except for MKI67
(r = 0.35, p = 0.10), SNAI2 (r = 0.43, p = 0.04) and PGR
(r = 0.52, p = 0.01) (Table 1). Upload of the full data set
to GSE73237 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE73237) allows investigators to assess
the correlation/variability of their genes of interest.
Effect of time to fixation on gene expression
Using class comparison method with false discovery rate
(FDR) <5 % no significant systematic differences in ex-
pression were found between samples A and B. How-
ever, 68 genes had a p <0.005 and fold change ≥1.25
(19 upregulated and 49 downregulated). Table 2 shows
the top eight of these genes ordered according to fold
change. The genes included early-response (RGS1, RGS2),
mitochondrial ATP synthase (ATP5C1) and stress-
response genes (DUSP1, FOSB). Ingenuity Pathway
Analysis (IPA) of the 68 genes, using Benjamini-Hochberg
multiple testing corrected B-H p value <0.05, identified six
canonical pathways (Additional file 2: Table S3A). These
were mainly associated with metabolism or signalling,
the most significant being oxidative phosphorylation
(B-H p value <0.005) and mitochondrial dysfunction
(B-H p value <0.005). The top networks identified also
included metabolism (Additional file 2: Table S3B).
Change in expression of 116 genes correlated with
time elapsed at p <0.005 (Additional file 2: Table S4) but
none were significant by their adjusted p value. IPA of
the 116 genes identified 28 pathways that were signifi-
cantly changed at p <0.05. The most significant were ad-
ipogenesis and mitochondrial dysfunction and the main
networks were inflammation and metabolic disease
(Additional file 2: Tables S5 and S6). There were only
two genes in common between the 68 (paired differences)
and 116 (time-elapsed) gene lists (SCD and AGPAT2 in-
volved in fatty acid biosynthesis).
Two of the 18 genes pre-selected as frequently re-
ported showed a modest but statistically significant
difference between samples A and B: BAG1 (mean
3 % decrease, p = 0.026), MAPT (mean 19 % decrease,
p = 0.007) (Table 1).
Analysis of candidate gene signatures and subtypes
There were no significant differences in the wound heal-
ing signature score [10] or an immune-response meta-
gene [9]. One of the 13 genes identified to be changing
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A. Study I
B. Study II
Fig. 1 Hierarchical clustering with Euclidean distance and average linkage based on a study I: clustering of 24,395 probes and 23 pairs of
samples; b study II: clustering of 32,332 probes and 56 pairs of samples. In brief, probes and samples were grouped based on similarities
calculated using the Euclidean distance method and average linkage (Additional file 1: Supplementary information). Sample dendrogram bars
were coloured according to PAM50 intrinsic subtypes and pairing of samples respectively. PAM50 color: green = normal; dark blue = LumA; light
blue = LumB; purple = Her2-enriched; red = basal; grey = paired together: light green = unpaired first sample; dark green = unpaired second sample.
LumA luminal A, LumB luminal B
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Table 1 Correlation of paired expression levels in five genes reported in breast cancer (complete list of 18 genes in Additional file 2: Table S2) and nine genes identified by Jeselsohn
STUDY I STUDY II STUDY I vs. STUDY II
Gene symbol R p value Geometric mean
of B/A
95 % CI R p value Geometric mean
of S/D
95 % CI Z value p value (2 tail)
BAG1 0.713 0.0001 0.971 0.946-0.996 0.734 <0.0001 1.043 0.984-1.106 -0.17 0.865
MKi67 0.354 0.0978 1.009 0.962-1.058 0.522 <0.0001 0.977 0.930-1.027 -0.8 0.4237
MAPT 0.847 <0.0001 0.806 0.692-0.938 0.811 <0.0001 1.108 0.965-1.273 0.44 0.6599
PGR 0.522 0.0106 1.093 0.946-1.263 0.824 <0.0001 0.978 0.894-1.070 -2.25 0.0244
SNAI2 0.430 0.0408 0.897 0.790-1.018 0.481 0.0002 0.940 0.838-1.054 -0.25 0.8026
Genes that significantly changed
in Jeselsohn et al. (2013) [6]
(a) immune related IGFBP2 0.583 0.0035 1.051 0.862-1.282 0.784 <0.0001 1.136 1.031-1.251 -1.48 0.1389
IL6 0.712 0.0001 1.108 1.003-1.223 0.194 0.1525 1.167 1.079-1.262 2.65 0.008
CD68 0.412 0.0509 1.065 0.889-1.272 0.464 0.0003 1.099 0.985-1.226 -0.25 0.8026
CD14 0.553 0.0062 1.047 0.905-1.211 0.355 0.0074 1.017 0.901-1.148 0.96 0.3371
CD52 0.755 <0.0001 1.085 0.923-1.276 0.436 0.0008 1.038 0.876-1.230 1.97 0.0488
CD44 0.458 0.0278 0.927 0.788-1.091 0.816 <0.0001 0.952 0.890-1.019 -2.48 0.0131
PPARG 0.315 0.1438 0.806 0.608-1.068 0.343 0.0096 0.993 0.870-1.132 -0.12 0.9045
ADM 0.476 0.0217 0.931 0.720-1.204 0.544 <0.0001 1.122 0.964-1.306 -0.35 0.7263
VEGFA 0.653 0.0007 1.043 0.967-1.124 0.647 <0.0001 0.991 0.930-1.055 0.04 0.9681
(b) non-immune related CENPF 0.781 <0.0001 1.039 0.913-1.183 0.729 <0.0001 1.062 0.959-1.176 0.46 0.6455
MYC 0.509 0.0132 1.076 0.897-1.292 0.65 <0.0001 1.439 1.241-1.668 -0.82 0.4122
CCNB1 0.413 0.0501 0.976 0.883-1.078 0.469 0.0003 1.010 0.919-1.107 -0.27 0.7872
MAP1LC3B 0.598 0.0026 0.957 0.882-1.038 0.809 <0.0001 0.971 0.933-1.010 -1.65 0.099
SNAI1 ND ND ND ND ND ND ND ND ND ND
ND non-detected
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in the Jeselsohn study (IL6) showed an 11 % increase
(Wilcoxon matched-pairs signed rank test: p = 0.014) be-
tween samples A and B [6].
Concordance for intrinsic subtypes between the sam-
ple pairs is shown in Additional file 2: Table S7. The ma-
jority of these ER+ samples were luminal, as expected.
Three tumours showed discordance between samples at
time point A and time point B: two luminal A (LumA)
samples at time point A were scored as luminal B
(LumB) or normal at time point B; one LumB at time
point A was rated as LumA at time point B. For each
tumour, we calculated the numerical differences in the
correlation coefficients to each of the LumA, LumB, and
HER2-enriched centroids for each of samples A and B.
As demonstrated in Additional file 3: Figure S4A, these
three cases with discordant intrinsic subtypes between
the time points A and B had the median values of nu-
meric difference between their LumA and LumB cen-
troid correlations of 0.08 and 0.32 when compared with
a median difference of 0.54 (95 % CI 0.17–0.61) and 0.52
(95 % CI 0.10–0.54) for the concordant samples at time
points A and B respectively.
Study II
From the 57 pairs, 56 passed microarray quality control
analysis. Patient demographics are described in Additional
file 2: Table S1.
Variability in gene expression between samples
Seventy-three per cent (41/56) of pairs clustered to-
gether on hierarchical clustering (Fig. 1b). The correl-
ation of the gene expression for the 32,332 probes
between the two samples ranged from 0.86 to >0.99 with
a median correlation of 0.97 (Additional file 3: Figure S5).
As in study I, we evaluated the Pearson correlation coeffi-
cients between paired expression levels on 18 selected
genes (Additional file 2: Table S2, Additional file 3:
Figure S6). The correlation was above >0.6 except for
SNAI2 (r = 0.48),MKI67 (r = 0.52), and GPR160 (r = 0.55).
Gene expression comparison between baseline and
surgery core
Thirty-nine genes (44 probes) were differentially
expressed between biopsies D and S at FDR <5 % and
fold change >1.25. The 39 genes included 11 early-
response genes (FOS, JUN, RGS1), six stress-response/
immune genes (DUSP1, GADD45B, ATF3), four
snoRNA (SNORD3C, SNORD3D), four haemoglobin
(HBA2, HBB) and five genes associated to breast cancer
progression (SIK1, TOB1, BHLHB2). Table 2 shows the
top eight genes identified. IPA analysis of the 39 genes
identified 76 pathways affected (B-H p value <0.05)
(Additional file 2: Table S8). Sixty per cent of the path-
ways identified were due solely to FOS and JUN. The
most common enriched networks were proliferation and
metabolism (Additional file 2: Table S9). None of the 18
pre-selected genes showed a statistically significant
change between samples D and S (Table 1).
Analysis of candidate gene signatures and subtypes
There were no significant differences in the wound heal-
ing signature [10] or the immune-response gene signa-
ture [9] between samples D and S. Of the 14 detected
significantly different genes described by Jeselsohn, two
immune-related genes (IL6 and IGFPB2) and one other
gene (MYC) were significantly increased in their expres-
sion in sample S by 17 %, 14 %, and 44 %, respectively.
The changes in IL6, IGFBP2 and MYC did not signifi-
cantly correlate with one another.
Most samples were luminal (Additional file 2:
Table S7B). Six of 39 (15 %) tumours classified as
LumA at baseline were classified as LumB at surgery, and
four of 14 tumours classified as LumB at baseline were
classified as LumA at surgery (29 %, 4/14). Among the 14
cases with discordant intrinsic subtypes between the base-
line and surgery, the median values of numeric difference
between their LumA and LumB centroid correlations
were 0.089 (95 % CI 0.02–0.49) and 0.031 (95 % CI
0.12–0.34) when compared with median values of 0.50
Table 2 Top eight genes significantly different in paired samples of study I and study II
STUDY I STUDY II
Accession Symbol Parametric p value FDR FC Accession Symbol Parametric p value FDR FC
NM_006732 FOSB 0.0014 0.138 2.08 NM_005252 FOS <1e-07 <1e-07 4.00
NM_004417 DUSP1 0.0003 0.133 1.72 NM_002922 RGS1 <1e-07 <1e-07 3.23
NM_002923 RGS2 0.0003 0.133 1.59 NM_004417 DUSP1 <1e-07 <1e-07 3.13
NM_003407 ZFP36 0.0005 0.133 1.54 NM_000517 HBA2 <1e-05 0.003 -2.90
NM_033027 AXUD1 0.0001 0.087 1.49 NM_000518 HBB <1e-05 0.006 -2.83
NM_004566 PFKFB3 0.0030 0.153 -1.48 NM_000517 HBA2 <1e-05 0.007 -2.64
NM_018955 UBB 0.0037 0.155 -1.46 NM_000558 HBA1 <1e-04 0.008 -2.39
NM_005063 SCD 0.0003 0.133 -1.45 NM_006732 FOSB <1e-06 0.001 2.38
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(95 % CI 0.26–0.55) and 0.50 (95 % CI 0.26–0.53) for the
concordant samples at baseline and surgery respectively
(Additional file 3: Figure S4B). Interestingly, the one
LumB/HER2-E subtype discordant case also had <0.3 be-
tween the LumB/HER2-E centroids.
Study I and study II common genes
Nine of the top 20 genes significantly different with
FDR <5 % and p <0.005 between samples D and S in
study II were also significant with a p <0.05 between
samples A and B in study I (Additional file 2: Table S10).
These included FOS, JUN and other early-response
genes.
The changes in gene expression for IL6 and PGR were
significantly different between study I and II (Fisher’s
r-to-z transformation, Table 1). IL6 expression corre-
lated positively between the two samples within study
I but not in study II. This was due to the difference
between the D and S samples varying substantially be-
tween tumours: there were large increases in IL6 ex-
pression in a minority of samples while others remain
largely unaffected (Fig. 2).
PGR expression was positively correlated between the
paired samples in both studies. There was a significant
tendency to an increase in study I (expression levels
higher in time point B than A) and a decrease in study
II (expression levels lower in time point S than D) that
resulted in a marginally significant (p = 0.024) heterogen-
eity between the studies.
Discussion
Multiple issues relating to intra-tumoural heterogeneity
are at the forefront of contemporary molecular path-
ology. One concerns the degree to which a single core-
cut biopsy can represent a biomarker’s expression across
the tumour. We assessed this using a genome-wide ap-
proach. We also determined whether two common clin-
ical practices around the time of surgery significantly
affected the expression of particular genes or activation
of certain pathways. Systematic changes resulting from
either process would be relevant to any studies of ex-
cised breast cancer, since virtually all excisions occur
after diagnostic core-cut and many will involve X-ray of
the tumour before its fixation/stabilisation. Data from
other studies may differ due to differences between the
analytical platforms used.
The variability in whole genome expression data
between tissue samples taken peri-surgically has been
studied in only small tumour sets (greatest number 13,
discussed below) [4–7]. Pure study of intra-tumoural
heterogeneity is best conducted by taking multiple sam-
ples from a tumour at the same time. However, the sys-
tematic changes occurring in our studies were very
modest and will have had little to no perceptible impact
on the overall correlations observed. The range of corre-
lations was similar across both studies and overall
provided data on 79 tumours. The poorest of the corre-
lations was 0.86 with the large majority being above 0.95
and several being >0.99. Thus gene expression overall
shows only modest variability across tumours.
Most investigators are more interested in the variation
in expression across the tumour for their gene or genes of
interest. Our on-line data (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE73237) will allow them to
evaluate that. For illustration we chose 18 genes frequently
studied in breast cancer. In general the correlation of the
individual genes between the samples was higher for those
genes with wide ranges, e.g. TFF1 (6-log2 range) and
ERBB2 (5-log2 range) than those with narrow ranges, e.g.
SNAI2 (1.5-log2 range) and MKI67 (<1.0-log2 range). The
correlations between individual genes were all worse than
those for the genome-wide analyses where there was an
approximately 8-log2 range of expression.
We have previously reported that the 60-minute delay
in fixation in study I had no significant impact on im-
munohistochemical expression of ER, PgR, Ki67, HER2,
Fig. 2 Line diagram of the paired IL6 expression levels in study I and study II. Study I IL6 expression levels of samples A and B and study II IL6
expression levels at diagnosis (D) and surgery (S). Marked in red are samples with >50 % increase in expression
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pAKT or pERK1/2 [2]. Similarly, no genes were found to
differ at an FDR <0.05. However, several genes related to
stress (e.g. DUSP1) and/or known as early-response
genes (e.g. RGS1, RGS2, and FOSB) were among those
most highly ranked according to change. In study II,
where the larger number of samples provided greater
statistical power, the same genes (e.g. RGS1, FOSB and
DUSP1) or similar genes (e.g. FOS) ranked in the top ten
genes with changed expression. This suggests that the
changes in these early-response and stress pathways
were true findings in both studies. It is important to
note for study II that no record was made in POETIC of
whether excised tumours were subject to X-ray before
taking of RNAlater-stored core-cuts. At the Royal
Marsden all impalpable tumours and most tumours
resected via wide excision (totalling about 50 % of
operations) are X-rayed. We have informally determined
that similar approaches are in place across the UK. Some
of the similarities in the genes changing between the
studies may therefore have been due to a proportion of
the tumours in study II being subjected to X-ray before
stabilisation. It should be noted, however, that while the
similarities in the gene changes between the two studies
are consistent with delays due to X-ray being responsible
in study II, there are multiple other factors that occur
around surgery that could also contribute. These include
the time taken for a sample to reach histopathology,
where some centres may have taken cores for the
POETIC study, and delays due to sentinel node biopsy,
which may have occurred prior to the core being taken.
Nonetheless the changes observed in study II are likely
to represent those that occur between diagnostic and
surgical samples in common practice and will affect the
measurement/study of early-response genes in excised
tumours.
Two smaller studies have assessed the impact of delay
to fixation on global gene expression [4, 5]. In the
Borgan study, changes in FOSB and JUND, while percep-
tible after 60 minutes, were much greater after 3 hours.
The correlation of these changes with time since tumour
removal make it likely that they are due to stress of tis-
sue cutting and/or its exposure changed oxygen tension
as opposed to the impact of other procedures around
surgery such as anaesthesia. The pathway and network
analyses undertaken with study I revealed changes in
oxidative phosphorylation and mitochondrial dysfunc-
tion. This is also consistent with the exposure of the
core-cuts to changed oxygen tension or ischaemia.
The correlation of mitochondrial dysfunction also cor-
related quantitatively with time between core-cut tak-
ing and fixation supports this change being causatively
associated.
Despite the lack of change in the pre-specified im-
mune signatures IL6 expression increased in both
studies and was among the genes identified by Jeselsohn
in a similar but smaller study. The change in IL6 levels
in study II was sufficiently heterogeneous between tu-
mours to nullify the highly significant correlation be-
tween the A and B samples in study I, suggesting
that the IL6 changes were more related to the effects
of the initial biopsy than to the short delays around
surgery. IL6 is a pleiotropic cytokine secreted by T
cells and macrophages in both systemic and localised
immune activation. Its role in breast cancer has been
reviewed by Dethlefsen and colleagues [12]. Changes
in IGFBP2 and particularly MYC in study II also con-
firmed those seen in the Jeselsohn study, but there
was little support for the other ten genes identified as
significant in that study. Like IL6 these two genes are
widely studied in breast cancer. Interpretation of data
on them must take account of the effects of diagnos-
tic biopsies.
Some smaller genome-wide analyses between paired
biopsies either side of surgery have been reported.
Riis et al. [7] studied 13 patients with the time be-
tween diagnostic and surgical samples ranging be-
tween 2 and 8 weeks. As in the current study genes
related to early response, including FOSB and to oxidative
stress including DUSP1 were differentially expressed be-
tween the two samples. Similar increases in early-response
genes including FOS were also reported in 16 patients in
whom fine-needle aspirates were taken presurgically and
immediately after tumour excision but the time between
samples was not stated [8]. Neither of these small studies,
identified IL6, IGFB2 or MYC as a changing gene but may
have been due to their low statistical power.
There were no systematic differences in categorisation
of the tumours into the intrinsic subgroups in either
study but discordance was noted between the luminal A
versus B subtypes, even after quality control of the
RNA and removing technical platform bias with nor-
malisation and standardisation of expression profiles.
In study II, 15–20 % of tumours considered luminal
A on one core-cut were typed as luminal B or
normal-like on the other. Allocation of subtypes is
made according to the highest correlation coefficient
with the archetypical centroid for each subtype irre-
spective of the proximity of the correlations to the
subtypes, although an early report [13] described 43/
115 (37 %) of tumours as having a low correlation to
any of the subtypes. Not surprisingly, we found that
subtype discordances were largely associated with
small differences between correlations with luminal A
and luminal B centroids. The level of discordance in
subtyping is important to appreciate given the prom-
inence of intrinsic subtyping in clinical studies of
breast cancer and its use for determining whether to
allocate chemotherapy [14].
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Conclusions
These studies of both random and systematic variability
of global gene expression in the context of presurgical
study of breast cancer have revealed modest differences
in most genes/pathways but confirmed substantial
changes in the expression of early-response genes that
appear to be due to ischaemia after surgery and in IL6,
IGFB2 and MYC that appear to be responses to initial
core-cut biopsy. The data are relevant to all studies
of breast cancer since excised tumours almost always
have been preceded by core-cut. We provide a refer-
ence source (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE73237) for others to assess the poten-
tial impact variability in the study of their own genes
of interest.
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